X

Thursday March 14, 2019 Presentations

STATE OF THE ART SPEAKER
Chair: Dan Hartman, MD, Bill & Melinda Gates Foundation, Kirkland, WA
Speaker: From Molecule to Patient: A Global Health Perspective
Penny Heaton, MD, Bill & Melinda Gates Medical Research Institute, Cambridge, MA

AWARD LECTURE: Rawls-Palmer Progress in Medicine Award Lecture
Award Presenter: Gregory L. Kearns, PhD, PharmD, Paradise Valley, AZ
Speaker: Progress in Pediatric Pharmacogenetics: Adults are Just Big Children
J Steven Leeder, PharmD, PhD, Children's Mercy Hospital, Kansas City, MO
 
FEATURED SPEAKER: 
Chair: Kellie Schoolar Reynolds, PharmD
Speaker: ACE, DPP4 and NEP Inhibitors: Understanding Mechanisms to Optimize Cardiovascular Benefit
Nancy J. Brown, MD, Vanderbilt University, Nashville, TN

WORKSHOP: Applications of Immunopharmacogenomics: Predicting, Preventing, and Understanding Immune-Mediated Adverse Drug Reactions
Chairs
Jason Karnes, PharmD, PhD, University of Arizona, Tucson, AZ
Ryan Funk, PharmD, PhD, University of Kansas Medical Center, Kansas City, KS
Speakers
Understanding Immune-Mediated Drug Toxicities: A Roadmap for Translation and Discovery with Emerging Treatments
Elizabeth Phillips, MD, Vanderbilt University, Nashville, TN
Predicting Immune-Mediated Adverse Drug Reactions and Emerging Immunogenetic Discoveries
Jason Karnes, PharmD, PhD, University of Arizona, Tucson, AZ
Preventing Immune-Mediated Adverse Drug Reactions: Large-Scale Translation of Immunopharmacogenomics
Munir Pirmohamed, PhD, University of Liverpool, Liverpool, United Kingdom
 
CAR-T Cells as Game Changers in Cancer Treatment: How Innovative Clinical and Translational Pharmacology Concepts Evolved Along with the Regulatory Framework to Expedite Treatments for Life-Threatening Diseases
Chairs
Ashit Trivedi, PhD, Amgen, Thousand Oaks, CA
Aline Barth, PhD, GlaxoSmithKline, Collegeville, PA
Speakers
The FDA’s Regulatory Framework for CAR-T Cell Therapies
Peter Marks, MD, PhD, US Food and Drug Administration, Silver Spring, MD

AWARD LECTURE: Oscar B. Hunter Career Award in Therapeutics Lecture
Award Presenter: Munir Pirmohamed, PhD, University of Liverpool, Liverpool, United Kingdom
Speaker: Clinical Pharmacogenetic Testing
Mary V. Relling, PharmD, St. Jude Children's Research Hospital, Memphis, TN

SYMPOSIUM: Physiologically Based Pharmacokinetic Modeling in Vulnerable Populations: Pregnant Women, Breastfeeding Infants, Neonates, and Young Children
Chairs:
Tamorah Lewis, MD, PhD, Children's Mercy Hospital, Kansas City, MO
Sara Quinney, PhD, Indiana University School of Medicine, Indianapolis, IN 
Speakers:
PBPK in Pregnant Women and Fetal Drug Exposure
Jashvant Unadkat, PhD, University of Washington School of Pharmacy, Seattle, WA
PBPK Modeling to Inform Drug Exposure in Breastfeeding Infants
Shinya Ito, MD, Hospital for Sick Children, Toronto, ON, Canada
Comparison of Various PBPK Models in Neonates: Research from the FDA Division of Pharmacometrics
Yaning Wang, PhD, US Food and Drug Administration, Silver Spring, MD
PBPK In Young Children: The Importance of Ontogeny Functions
Jean Dinh, PharmD, PhD, Children's Mercy Hospital, Kansas City, MO

Ready for Prime Time: Implementing Adherence Programs in Drug Development and Post Approval Settings
Chairs
Terrence Blaschke, MD, Stanford University, Stanford, CA
Rada Savic, PhD, University of California, San Francisco, San Francisco, CA
 
Speakers
Versatility and Scalability of Solutions to Monitor and Improve Medication Adherence
Bruce V. Thomas, JD, The Arcady Group, Richmond, VA
Insights From Monitoring Adherence in Clinical Trials and in Clinical Care: Understanding the Key Question of Drug Forgiveness
Bernard Vrijens, PhD, AARDEX Group, Visé, Belgium
Controlling Tuberculosis: The Impact of Interventions to Improve Adherence in High-Burden, Low-Income Settings
Rada Savic, PhD, University of California, San Francisco, San Francisco, CA
Optimizing Adherence Monitoring to Support Differentiated Care, Better Efficiency and Improved Outcomes
Jessica Haberer, MD, Massachusetts General Hospital, Boston, MA

How Artificial Intelligence and Machine Learning Techniques Are Revolutionizing Drug Discovery and Development
Chairs
Islam Younis, PhD, Astellas Pharma, Northbrook, IL
Ahmed Othman, PhD, AbbVie, North Chicago, IL
Speakers
The Rise of Deep Learning in Drug Discovery
Russ Altman, MD, PhD, Stanford University, Stanford, CA
The Most Promising Areas of Machine Learning in Drug Development
James Dunyak, PhD, AstraZeneca, Waltham, MA
Application of Machine Learning to Predict Clinical Activity of Drug Combinations
Yuanfang Guan, PhD, The University of Michigan, Ann Arbor, MI
Potential Application of Machine Learning in Regulatory Setting
Qi Liu, PhD, US Food and Drug Administration, Silver Spring, MD


Photo Gallery
Recent News
  • ASCPT 2019 Annual Meeting Pre-conferences
    June 25, 2019
  • Upcoming Journal Review Club
    June 25, 2019
  • ASCPT Members-Only Webinar presented by the Regulatory Science (RS) Community and Membrane Transporter (MT) Community
    June 20, 2019
Contact Us